Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
News|Articles|July 31, 2023
Free Webinar: Urinary Incontinence Essentials for Primary Care
Author(s)American Urogynecologic Society
Join Dr. Catherine Bradley, urogynecologist at the University of Iowa Hospitals and Clinics, as she discusses common types of female urinary incontinence seen in practice.
Advertisement
Monday, August 7
7:00 – 8:00 pm ET
Speaker: Catherine Bradley, MD | University of Iowa Hospital and Clinics
During this
Key Takeaways:
- Understand common types of female urinary incontinence seen in primary care practice.
- Describe the initial evaluation, diagnosis, and treatment of urinary incontinence.
- Identify advanced treatment options and resources to support patients who don't respond to initial treatments.
Advertisement
Related to this article
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
2
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
3
LUGPA 2026: Midterms, AI, and ancillary services take center stage
4
CLARIFY trial reaches enrollment target for 64Cu-SAR-bisPSMA in prostate cancer
5